Loading
DNA End-joining Repair / Molecular Targeted Therapy / Dna-directed DNA Polymerase · Journal article
Cancer Biology & Therapy · July 28, 2026
A consensus or society position rather than new primary data.
This is a narrative review of DNA polymerase theta (Polθ) as an emerging therapeutic target in cancer, covering its structure, function, expression patterns, and the rationale for synthetic lethal and inhibitor-based approaches. The source describes Polθ overexpression in many cancers and notes that clinical trials are underway, but provides no original efficacy data, effect sizes, or trial outcomes.
Narrative review. Cancer patients and normal tissues (descriptive context; no trial cohort specified)..
Polθ is essential for microhomology-mediated end joining (MMEJ), a backup DNA double-strand break repair pathway. Polθ is barely expressed in normal tissues but overexpressed in many cancers. Polθ inhibitors and related therapeutic strategies have emerged in recent years with clinical trials underway.
No comparative efficacy or safety data between Polθ inhibitors and standard therapies provided.
This review provides clinicians and researchers with a comprehensive overview of Polθ biology and emerging therapeutic opportunities, but does not report empirical trial data to guide clinical decision-making. Readers should consult primary trial publications for efficacy and safety evidence.
A narrative review synthesizing current knowledge on Polθ biology, therapeutic rationale, and drug development status—informative for researchers and clinicians but not reporting original empirical data or trial outcomes.
As stated by the source record.
This review provides clinicians and researchers with a comprehensive overview of Polθ biology and emerging therapeutic opportunities, but does not report empirical trial data to guide clinical decision-making. Readers should consult primary trial publications for efficacy and safety evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
DNA double-strand breaks (DSBs) are the most severe DNA damage, and defective repair can lead to apoptosis or malignant transformation. DSBs are mainly repaired by nonhomologous end joining (NHEJ) and homologous recombination (HR), while microhomology-mediated end joining (MMEJ) serves as a backup pathway. Since DNA polymerase theta (Polθ) is essential for MMEJ, this pathway is also named Polθ-mediated end joining. Polθ is barely expressed in normal tissues but overexpressed in many cancers, making it a promising therapeutic target. In recent years, Polθ inhibitors and related therapeutic strategies have emerged rapidly, with clinical trials underway. This review summarizes the structure, function and expression of Polθ in tumorigenesis, highlights synthetic lethal strategies, drug development and clinical translation, and discusses current limitations and future directions for cancer research.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.